The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.

Meanwhile, Exelixis and AstraZeneca continue to invest in pivotal trials of blockbuster follow-ons.

TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.

Final survival analysis draws a blank, and Lantheus throws in the towel.

Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.

Conference activity picks up, with the big one – ASCO – at the end of the month.